Create
Query
event_store.db
—
signals
actions
agent_runs
approvals
artifacts
commitments
constraints
conversation_compaction
conversation_state
conversation_turns
dead_letters
decisions
deliveries
effects
email_messages
email_reply_drafts
email_threads
entities
entity_aliases
entity_tags
episode_context_index
episodes
event_subjects
events
events_archive
fact_sources
facts
inbox_items
inbox_links
intel_memory
jobs
leader_leases
links
memory_candidates
memory_embeddings
memory_items
memory_items_fts
(v)
memory_items_fts_config
memory_items_fts_data
memory_items_fts_idx
opportunity_memory
pending_interactions
proposal_sources
proposals
reminders
schedules
schema_migrations
signal_candidates
signal_fps
signals
sms_conversations
sms_messages
sms_reply_drafts
source_cursors
sources
sqlite_sequence
sqlite_stat1
stream_cursors
threads
watchers
Toggle helper tables
memory_items_fts_content
memory_items_fts_docsize
memory_items_fts_segdir
memory_items_fts_segments
memory_items_fts_stat
Structure
Content
Query
Insert
Drop
Import
Export
Update row sig_c0421f3e6df2 in signals
id
sig_c0421f3e6df2
Primary key.
TEXT
event_id
128718
TEXT NOT NULL
watcher_id
NULL
TEXT
signal_type
discovery_sec_filing_delta
TEXT NOT NULL
value
{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1590750/0001193125-26-160344.txt","as_of":"2026-04-18T03:05:05.644967+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1590750/0001193125-26-160344.txt","company":"Viridian Therapeutics, Inc.\\DE","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1590750/0001193125-26-160344.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_5849504e97dea372","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1590750/0001193125-26-160344.txt","content_type":"text/plain","enriched_at":"2026-04-18T03:19:54.927634+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"DEF 14A","final_url":"https://www.sec.gov/Archives/edgar/data/1590750/0001193125-26-160344.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1590750/0001193125-26-160344.txt","source_event_id":"evt_50ee6915ada1","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"DEF 14A","fp":"0cef2a1870985d58","kind":"sec_filing","published_at":"20260417","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-06-02","2026-04-07","2026-04-17","2026-04-18"],"entities":[{"asset_class":"equity","name":"Viridian Therapeutics, Inc.","relevance":"high","symbol":"VRDN","type":"issuer"},{"asset_class":"other","name":"U.S. Securities and Exchange Commission (SEC)","relevance":"medium","symbol":"","type":"regulator"},{"asset_class":"other","name":"VirtualShareholderMeeting.com","relevance":"low","symbol":"","type":"meeting_platform"}],"event_type":"listing","information_gaps":["The specific proposals/items included in the proxy statement are not present in the provided text excerpt (e.g., director nominees, voting matters).","The excerpt does not describe any changes versus a prior known state beyond the fact that this DEF 14A was filed.","No details are provided about executive compensation or equity compensation utilization beyond general forward-looking statement language."],"key_facts":["Form DEF 14A is a proxy statement for Viridian Therapeutics, Inc. (the \u201cCompany\u201d).","The 2026 Annual Meeting of Stockholders will be held on Tuesday, June 2, 2026 at 2:00 p.m. Eastern Time.","The Annual Meeting will be a virtual meeting conducted exclusively online via live audio webcast at www.virtualshareholdermeeting.com/VRDN2026.","The Board fixed April 7, 2026 as the record date.","Only stockholders of record at the close of business on April 7, 2026 are entitled to notice of, and to vote at, the Annual Meeting (and any adjournment or postponement).","The proxy materials are first being made available to stockholders on or about April 17, 2026.","The proxy materials are furnished primarily via the internet pursuant to SEC rules (instead of mailing printed copies)."],"numeric_claims":[{"label":"Annual Meeting date","value":"2026-06-02"},{"label":"Annual Meeting time (ET)","value":"2:00 p.m."},{"label":"Record date","value":"2026-04-07"},{"label":"Proxy materials availability date (approx.)","value":"2026-04-17"}],"primary_claim":"Viridian Therapeutics, Inc. filed Form DEF 14A for its 2026 Annual Meeting of Stockholders, scheduled for June 2, 2026 (virtual) with a record date of April 7, 2026.","relevance_score":0.55,"sentiment":"neutral","source_quality":"high","summary":"Viridian Therapeutics, Inc. filed a DEF 14A proxy statement for its 2026 Annual Meeting of Stockholders. The filing states the meeting will be held virtually on June 2, 2026, with April 7, 2026 as the record date.","topics":["SEC filing","DEF 14A","proxy statement","annual meeting","virtual meeting","record date","stockholder voting"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form DEF 14A \u00b7 Viridian Therapeutics, Inc.\\DE \u00b7 Filed 20260417","ticker":"VRDN","tickers":["VRDN"],"title":"VRDN filed DEF 14A","url":"https://www.sec.gov/Archives/edgar/data/1590750/0001193125-26-160344.txt"}
TEXT NOT NULL
threshold
NULL
TEXT
direction
NULL
TEXT
severity
NULL
TEXT
window
NULL
TEXT
source
discovery_sec_filings
TEXT NOT NULL
reason_trace
{"_evidence_event_ids":["evt_50ee6915ada1"]}
TEXT
dedupe_key
signal_enriched:discovery_sec_filing_delta:b5301901908fefd8
TEXT NOT NULL
throttle_s
INTEGER (default 0
created_at
2026-04-18T03:05:05.644967+00:00
TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')
Update
Cancel